Inhaled Iloprost for Suspected COVID-19 Respiratory Failure
ILOCOVID
Inhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory Failure
1 other identifier
interventional
40
1 country
1
Brief Summary
Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2 covid19
Started May 2020
Typical duration for phase_2 covid19
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 23, 2020
CompletedFirst Submitted
Initial submission to the registry
June 9, 2020
CompletedFirst Posted
Study publicly available on registry
June 24, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2021
CompletedMarch 29, 2022
May 1, 2020
1 year
June 9, 2020
March 26, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
change in oxygenation parameters
change in oxygen saturation and PaO2/FiO2 ratio by 20% on day 6 compared to baseline values prior to Iloprost initiation.
5 days
Secondary Outcomes (7)
Rates of endotracheal intubation
28 days
Invasive ventilation duration
28 days
ICU length of stay
28 days
Hospital Length of stay
28 days
Rates of proning therapy
28 days
- +2 more secondary outcomes
Study Arms (1)
Inhaled Iloprost therapy
EXPERIMENTALInhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization
Interventions
Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
Eligibility Criteria
You may qualify if:
- Suspected or confirmed COVID-19 patient by PCR
- O2 saturation =\<92% on 5 or more l/min of O2 by NC or Face mask
- On CPAP, HFNC or Invasive ventilation
- Enrollment within 48h of onset of hypoxemia
You may not qualify if:
- Age \<18
- Pregnancy or Positive pregnancy test at the time of screening
- Clinical evidence of left atrial hypertension or known chronic CHF
- Persistent Hypotension SBP\<85 on presentation
- Mechanical ventilation \>7 days
- Patients who received iloprost treatment for any indication within 48 hours prior to enrollment in the clinical trial or patients who were on thrombin inhibitors, or nitric oxide within the previous 24 h before study randomization are also excluded.
- Patients with contraindication for ilioprost
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hamad Medical Corporation
Doha, Qatar
Related Publications (1)
Mulia EPB, Luke K. Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale. Egypt Heart J. 2021 Sep 16;73(1):82. doi: 10.1186/s43044-021-00208-y.
PMID: 34529182DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nadir Kharma, MD
Hamad Medical Corporation
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 9, 2020
First Posted
June 24, 2020
Study Start
May 23, 2020
Primary Completion
May 31, 2021
Study Completion
May 31, 2021
Last Updated
March 29, 2022
Record last verified: 2020-05